Psomagen, Inc. (KOSDAQ:950200)

South Korea · Delayed Price · Currency is KRW

2,970.00

+40.00 (1.37%)

At close: Oct 16, 2026

Market Cap	57.13B -19.4%
Revenue (ttm)	60.70B +33.5%
Net Income	-1.59B
EPS	-79.24
Shares Out	19.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,122
Open	2,950.00
Previous Close	2,930.00
Day's Range	2,905.00 - 3,030.00
52-Week Range	2,380.00 - 4,690.00
Beta	-0.20
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Psomagen

Psomagen, Inc. engages in the provision omics solutions and contract laboratory services. The company’s research services includes genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; single-cell analysis, research in suspensions, biological fluids, tissues, or cell populations; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its expression ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2004

Employees 90

Stock Exchange KOSDAQ

Ticker Symbol 950200

Full Company Profile

Financial Performance

In 2025, Psomagen's revenue was 59.19 billion, an increase of 35.56% compared to the previous year's 43.66 billion. Losses were -2.98 billion, -46.90% less than in 2024.

Financial Statements